Introduction
Cancer patients have a higher risk of developing venous thromboembolism (VTE) than patients without cancer, and VTE has a negative impact on the survival of cancer patients (1) (2) (3) (4) (5) (6) . However, the VTE risk among cancer patients differs considerably (3, 5) and is below 10% even in certain patient groups with advanced cancer (7) . Therefore, predictive parameters are required to stratify patients into risk groups. Within the last years, clinical research on prediction of cancer-associated VTE has focused on clinical and laboratory parameters (8) (9) (10) (11) (12) (13) (14) . Based on laboratory and clinical parameters associated with VTE, a scoring model for the prediction of VTE in cancer patients was recently developed (15) and already expanded (16) and validated (17) in other study populations. However, in regard to the heterogeneity of cancer patients an improved predictability and a better understanding of the underlying pathomechanisms of cancer-associated VTE are desirable. Especially routine parameters that are usually available at initial diagnosis of every cancer patient could help the oncologist to better assess the VTE risk of each individual patient.
Patients with advanced cancer have an elevated risk of developing VTE. Distant metastases in cancer patients are among the strongest risk factors for cancerassociated VTE (3, 18, 19) . However, usually lymph node metastases are not regarded as an established risk factor (5, 20, 21) . Studies in patients of the Californian Cancer Registry investigated the association between VTE and local, regional, and distant stage in a group of different cancer sites (19) and in several single tumor entities (22) (23) (24) (25) (26) (27) . The risk was highest in patients with metastatic disease, but also slightly elevated in patients with regional disease, compared to those with localized cancer only. As these studies are based on registry data obtained between DOI: 10.3324/haematol.2012.073338 factors, could not be considered.
Moreover, to our knowledge there are no studies that comprehensively investigated the relationship between predictive laboratory biomarkers of cancer-associated VTE and tumor stage, so to elucidate the pathophysiology of the association between coagulation and malignancy.
We hypothesize that the presence of lymph node metastases is a strong risk factor for VTE and is associated with increased levels of predictive biomarkers for cancerassociated VTE. To test this hypothesis, we prospectively followed 832 cancer patients and investigated the relationship between local (N0), regional (N1-3), and distant (M1) cancer stages and the occurrence of VTE. Furthermore, we correlated all known established plasma biomarkers, that are predictive of cancer-associated VTE, namely D-dimer (8) , prothrombin fragment 1 and 2 (F1 + F2) (8) , clotting factor VIII (FVIII) (13) , platelets (15), soluble P-selectin (sP-selectin) (9), leukocytes (15) and hemoglobin (15) with local, regional, and distant cancer stages, to elucidate the pathogenesis of the prothrombotic state in patients with regional stage, and to establish possible links between the hemostatic system and the process of metastatic dissemination.
Methods
The Vienna Cancer and Thrombosis Study (CATS) is an ongoing, prospective and observational cohort study at the Medical University of Vienna and is conducted in accordance with the Declaration of Helsinki after approval by the institutional ethics committee. The aim of CATS is to investigate factors which are associated with the Study participants underwent tumor staging or, in case of disease progression after remission, re-staging prior to study inclusion. The study participants were followed prospectively until the end of follow-up (2 years), occurrence of VTE, death, loss of follow-up, or withdrawal of consent. At study inclusion, venous blood samples were drawn and patients' medical history was recorded.
Based on the TNM Classification specified by the Union for International Cancer Control (UICC) (28) we defined 3 tumor stages: local, regional, and distant. Patients with absence of lymph node metastases and absence of distant metastases were classified as local stage (TxN0M0). Regional stage was defined by a positive lymph node status but concurrent absence of distant metastases (TxN1-3M0). The presence of distant metastases led to the classification of distant stage, irrespective of the lymph node status (TxNxM1). Lymph node metastases and distant metastases were detected and verified by imaging techniques (e.g. computerized tomography), cancer biopsy, or cancer surgery. Characteristics of patients were described by median and interquartile-range (IQR) because of non-normally distributed continuous variables, and by frequencies and percentages for categorical variables. The Kruskal-Wallis test was applied to compare the distribution of (non-normally distributed) biomarkers. In case of a significant overall test result, a Mann-Whitney test was applied and corrected with a Bonferroni correction. The median of the follow-up distribution was estimated by the Kaplan-Meier method with reverse meaning of the status indicator (29 enabling an easy practicability in clinical routine laboratory biomarkers were dichotomized according to cut-off levels used in the Khorana VTE prediction score (15) and in case of D-dimer according to the 75th percentile of the CATS study population (8) . More detailed information is available online (Supplemental file).
Results

Study population
All patients with solid tumors included in the CATS between October 2003 and December 2009 (n=968) were eligible for this study. A total of 136 of these patients had to be excluded: 90 patients did not match the exact inclusion criteria after reevaluation, in 39 patients no follow-up was available, and 7 patients were excluded because of incomplete information on tumor stage. Hence, in total 832 patients with solid tumors were enrolled (Table 1) . 
Thromboembolic events
In 57 (6.9%) patients a clinically relevant VTE was detected. A deep vein thrombosis (DVT) of the lower extremity was diagnosed in 22, pulmonary embolism (PE) in 20, and a combined DVT and PE in 3 patients. An isolated DVT of the upper extremity was detected in 2 patients. Each of the following events was diagnosed in one patient: combined DVT of the lower extremity and portal vein thrombosis, combined DVT of the upper extremity and PE, internal jugular vein thrombosis, and sinus vein thrombosis. PE was fatal in 2 patients. A portal vein thrombosis was diagnosed in 4 patients. All portal vein thromboses occurred in patients with pancreatic cancer: 1 in local and regional cancer each, and 2 in metastatic cancer. Of the 57 VTE events, several events were detected incidentally: 7 PEs, 2 portal vein thromboses, 1 internal jugular vein thrombosis, and 1 deep vein thrombosis (DVT) of the lower extremity.
Nevertheless, they were rated as clinically relevant by the adjudication committee.
The overall cumulative incidence of VTE was 4.9% after 6 months, 6.0% after 12 months, and 6.9 % after 2 years. 
Risk of VTE: Tumor stage
Seven (2.9%) patients with local, 12 (8.7%) with regional, and 38 (8.4%) with distant stage developed symptomatic VTE during follow-up. In Kaplan-Meier analysis, the cumulative probability of VTE after 6 months was 2.1% in patients with local, 6.5% in patients with regional, and 6.0% in patients with distant stage ( (Table 2) .
Furthermore, we performed a separate evaluation of the frequency of VTE in the 3 different regional lymph node stages N1, N2, and N3. Of 91 patients with N1 status 8 patients (8.8%) and of 38 patients with N2 status 4 patients (10.5%) developed VTE during the follow-up period. None of the 9 patients with N3 status developed VTE.
Association of tumor stage with biomarkers
Patients with local, regional, or distant stage had significantly different levels of all analyzed biomarkers (D-dimer, F1+F2, FVIII, platelets, sP-selectin, leukocytes, and hemoglobin; all P<0.0068). D-dimer levels, FVIII activity, and platelet counts DOI: 10.3324/haematol.2012.073338 continuously increased from local to regional to distant stage, whereas hemoglobin levels continuously decreased. No continuous increase from local to regional to distant stage was found for leukocyte counts, F1+2, and sP-selectin levels.
Compared to patients with local stage, patients with regional stage had significantly higher D-dimer levels (P<0.001), platelet counts (P=0.002), and FVIII activity (P=0.021), and lower levels of hemoglobin (P<0.001). Levels of F1+2, and leukocyte counts were not significantly elevated in patients with regional stage. Compared to patients with local stage, in patients with distant stage all biomarkers were significantly increased, while hemoglobin was significantly decreased ( Table 3) .
Risk of VTE: Tumor stage and routinely available biomarkers
To consider selected laboratory biomarkers in the multivariable analysis, a second Table 4) .
Discussion
In this prospective study we demonstrate that regional lymph node metastases are a strong risk factor for cancer-associated VTE. Furthermore, a significant relationship DOI: 10.3324/haematol.2012.073338 between biomarkers predictive of cancer-related VTE and regional tumor stage is shown.
In our study, we were especially interested in the association between lymph node metastases and the occurrence of VTE. We therefore applied the TNM classification to elucidate the relationship between local (N0), regional (N1-3), and distant stage (M1), and the occurrence of VTE. Previous studies paid only little attention to the clinical relevance of regional lymph node metastases as a risk factor for VTE in cancer patients. To our knowledge there are only the studies of the Californian Cancer Registry (CCR) that investigated the association between local, regional, and distant stage and occurrence of VTE (19, (22) (23) (24) (25) (26) (27) . Studies of the CCR that focused on tumor sites similar to those included in CATS (lung, colon, stomach, pancreatic, breast, and prostate) reported an about 2-fold higher risk of VTE in patients with regional stage than in those with local stage (odds ratios ranging from 1.1 in patients with pancreatic cancer to 2.7 in patients with colon cancer) (19, (22) (23) (24) . Interestingly, in our study the VTE risk in patients with regional stage was clearly higher. We found that patients with regional stage cancer had a 3-4-fold higher risk of developing VTE than those with local stage cancer. In Kaplan-Meier analysis the cumulative risk of VTE after 6 months was even slightly higher in patients with regional lymph node metastases than in patients with distant metastases.
An explanation for the considerably higher risk of VTE in regional stage cancer patients in CATS might be that the CCR studies are based on registry data, whereas CATS is a prospective study specifically designed to identify predictive parameters for cancer-associated VTE. We verified patients' exact TNM status at study inclusion and documented type and duration of patients' anti-cancer therapies during followup. To eliminate the confounding influence of anti-cancer therapies on the occurrence of VTE, we adjusted for surgery, chemotherapy, and radiotherapy in time-
dependent Cox-regression analyses, and the HR of regional lymph node metastases for VTE remained similarly high.
It has been shown that the VTE risk in cancer patients is highest in the first 6 months after diagnosis (3) . Therefore, the inclusion of patients with progression of disease after remission in our study might be a possible confounder, biasing the VTE risk in patients with regional and distant stage. Hence, we adjusted for newly diagnosed cancer (versus progression of disease) in the multivariable analyses. However, patients with newly diagnosed cancer did not have a significantly higher risk of VTE than patients with progression of disease after complete or partial remission.
The high VTE incidence in patients with regional stage in our study was not caused by bulky lymph nodes obstructing the venous flow. However, in 1 patient with regional pancreatic cancer a local obstruction of venous flow by the primary tumor or regional lymph node metastases could not be definitely excluded, since VTE occurred in the portal vein.
Moreover, to consider selected laboratory biomarkers in the multivariable analysis, we performed a second Cox-regression model. The model included predictive biomarkers for cancer-associated VTE that are easy to determine and are routinely available in almost all hospital laboratories. Also in this extended model lymph node metastases were independently and strongly associated with the occurrence of VTE.
The HR of VTE for lymph node metastases in model 2 was similar high to the HR of VTE for distant metastases in model 2, emphasizing again the relevance of lymph node metastases as a strong risk factor for cancer-associated VTE.
To explain and understand the considerably elevated VTE risk in patients with regional stage it is helpful to take a closer look at the process of metastatic between tumor cells and the hemostatic system precede the manifestation of distant metastases. Thus, a hypercoagulable state in cancer patients may already exists in patients with regional spread. To support this approach for explaining the prothrombotic state in patients with regional stage, and to establish possible links between the hemostatic system and the process of metastatic dissemination, we correlated biomarkers that are predictive of cancer-associated VTE with local, regional, and distant stage.
In our investigations, D-dimer was already elevated in regional stage. This clearly confirms the assumption of a hypercoagulable state in patients with regional disease.
These results are in line with the data of other studies that found a correlation between tumor stage and D-dimer in breast cancer patients (30) and colorectal cancer patients (31) . Interestingly, F1+2 was elevated only in distant stage, but not in regional stage. That in patients with regional stage D-dimer levels were increased, while F1+2 levels were not increased, indicates that tumors might induce a hypercoagulable state in patients with regional disease by interaction with the fibrinolytic system. This is supported by the fact that malignant cells can activate coagulation in cancer patients by dysregulating fibrinolytic pathways (32) . Clotting factor VIII activity and platelets were elevated in regional and distant stage. We hypothesize that these factors might play an important role in the early phase of metastatic dissemination. In contrast, sP-selectin and leukocytes were elevated in distant stage only, suggesting that sP-selectin and inflammatory processes might play a more important role in the late phase of metastatic dissemination. In accordance with our findings, Connolly et al. demonstrated an association between pre-chemotherapy leukocytosis and distant metastases in a prospective observational study in patients with different types of malignancies (33) . Low hemoglobin is a predictive parameter for cancer-associated VTE and it is even part of DOI: 10.3324/haematol.2012.073338 the Khorana VTE prediction score (15) . For this reason we also investigated the association between hemoglobin and tumor stage. Hemoglobin was decreased in regional and distant stage.
There are several limitations of our study. The tumor stage was collected only at study inclusion. We did not re-evaluate the stage at the time point of occurrence of VTE. However, most of all VTE events (72%) in our study occurred in the first 6 months. Moreover, the heterogeneity of our study participants implies that our results can be applied only to patients similar to our cohort. Due to the relatively small number of VTE events in each tumor entity, we were not able to analyze the association between tumor stage and the occurrence of VTE in single tumor sites.
Based on the findings of this study, we recommend an equally high alertness for symptoms compatible with VTE in patients with regional stage as in those with metastatic stage. Similar to patients with distant metastases, also patients with regional stage should be regarded as patients at high risk of VTE, especially in the presence of other risk factors for cancer-associated VTE.
We conclude that cancer patients with regional lymph node metastases have an increased risk of developing VTE. Elevated levels of predictive biomarkers in regional stage underpin our results and are in line with the activation of the hemostatic system in the early phase of metastatic dissemination. structured interview, patients' medical history was recorded, and blood samples were drawn.
Outcome measure and diagnosis of venous thromboembolism
The main outcome measure was the occurrence of symptomatic VTE within two years after study inclusion. No routine screening for VTE was performed. All patients were briefed about VTE and asked to immediately report to our clinic, if they recognized any VTE symptoms. Additionally, we contacted every patient approximately every 3 to 4 months to perform a follow-up. When a patient presented with symptoms of VTE, objective methods were used to confirm the diagnosis of VTE. Duplex sonography or venography were applied for diagnosis of deep vein thrombosis (DVT), and computed tomography or ventilation/perfusion lung scan were applied for diagnosis of pulmonary embolism (PE). An independent adjudication committee consisting of experts in the fields of angiology, radiology, and nuclear medicine evaluated and approved all VTE events. These experts were informed about patients' medical history, but were unaware of tumor stage and laboratory results. Incidentally detected VTE (e.g. PE detected in a routine computerized tomography) was counted as an event, when the adjudication committee decided that the event was of clinical significance.
Classification of local, regional and distant stage
Based on the TNM Classification specified by the Union for International Cancer 
